Thus, simple administration of Nrf2 enhancers may not maintain the same benefit as exercise and clinical trials of such compounds would do well to include exercise/non-exercise groups whenever possible to determine the effect of this systemic machinery on cardiac hypertrophy. This evidence concerns the gene NFE2L2 and cardiac hypertrophy.